Spectral Medical Inc (EDT:CA) is a late stage theranostic company developing diagnostics and therapies for septic shock. Its lead product combines an Endotoxin Activity Assay with the Toraymyxin™ hemoperfusion device to remove endotoxin from the bloodstream.
Before we dive in, we have a special offer! For a limited time, you can get 70% off Stock Target Advisor’s premium features. Claim your discount here!
Expected Quarterly Earnings Report of Spectral Med Inc:
- Report date: before the market opens on Wednesday, March 26, 2025
- Quarter: fourth quarter 2024
- Consensus EPS loss: approximately C$0.04 per share
- Consensus revenue: roughly C$0.50 million
Stock Target Advisor’s Analysis on Spectral Med Inc:
Overall Rating: Slightly Bullish
What We Like
- High market capitalization within the Diagnostics & Research sector
- Top quartile risk adjusted returns over 12 months
- Low volatility relative to peers
- Superior earnings growth over five years
What We Do Not Like
- Trading at a premium on price to book value
- Negative operating cash flow in the past four quarters
- Negative free cash flow in the past four quarters
Stock Target Advisor also highlights Spectral’s 62.96% total return over the past year, ranking it first in its sector, and cites a Mackie Research target price of CAD 2.50
Conclusion:
Investors will focus on enrollment progress in Spectral’s pivotal Phase 3 Tigris trial and cash runway when Q4 results are released on March 26. With strong sector leadership and a bullish technical profile, the earnings report is a key catalyst for Spectral Medical’s valuation.
Muzzammil is a content writer at Stock Target Advisor. He has been writing stock news and analysis at Stock Target Advisor since 2023 and has worked in the financial domain in various roles since 2020. He has previously worked on an equity research firm that analyzed companies listed on the stock markets in the U.S. and Canada and performed fundamental and qualitative analyses of management strength, business strategy, and product/services forecast as indicated by major brokers covering the stock.
